A detailed history of Vanguard Group Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,288,740 shares of ERAS stock, worth $35.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,288,740
Previous 10,351,746 28.37%
Holding current value
$35.1 Million
Previous $24.4 Million 48.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.17 - $3.28 $6.37 Million - $9.63 Million
2,936,994 Added 28.37%
13,288,740 $36.3 Million
Q2 2024

Aug 13, 2024

BUY
$1.79 - $2.63 $10.8 Million - $15.8 Million
6,013,638 Added 138.62%
10,351,746 $24.4 Million
Q1 2024

May 10, 2024

BUY
$1.67 - $2.55 $911,427 - $1.39 Million
545,765 Added 14.39%
4,338,108 $8.94 Million
Q4 2023

Feb 14, 2024

SELL
$1.67 - $2.49 $2.21 Million - $3.29 Million
-1,322,769 Reduced 25.86%
3,792,343 $8.08 Million
Q3 2023

Nov 14, 2023

SELL
$1.97 - $2.91 $2.97 Million - $4.39 Million
-1,508,119 Reduced 22.77%
5,115,112 $10.1 Million
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $1.49 Million - $1.91 Million
579,443 Added 9.59%
6,623,231 $18.3 Million
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $597,961 - $968,958
218,234 Added 3.75%
6,043,788 $18.2 Million
Q4 2022

Feb 10, 2023

BUY
$3.89 - $8.57 $873,157 - $1.92 Million
224,462 Added 4.01%
5,825,554 $25.1 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $3.35 Million - $6.14 Million
575,333 Added 11.45%
5,601,092 $43.7 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $452,939 - $862,364
98,895 Added 2.01%
5,025,759 $28 Million
Q1 2022

May 13, 2022

BUY
$8.6 - $15.48 $28.4 Million - $51.1 Million
3,299,572 Added 202.76%
4,926,864 $42.4 Million
Q4 2021

Feb 14, 2022

SELL
$12.51 - $22.75 $5 Million - $9.09 Million
-399,479 Reduced 19.71%
1,627,292 $25.4 Million
Q3 2021

Nov 12, 2021

BUY
$17.43 - $24.34 $35.3 Million - $49.3 Million
2,026,771 New
2,026,771 $43 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $322M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.